S&P Futures
5,887.25 -9.00 (-0.15%) Dow Futures
43,131.00 -46.00 (-0.11%) Nasdaq Futures
20,471.75 -47.75 (-0.23%) Russell 2000 Futures
2,250.20 -5.30 (-0.23%) Crude Oil
70.27 -0.29 (-0.41%) Gold
2,743.00 +4.10 (+0.15%)
NurExone Biologic Inc. (NRX.V)
- Zacks Small Cap Research
Initiating Coverage of NRXBF
By Brad Sorensen, CFA OTC:NRXBF READ THE FULL NRXBF RESEARCH REPORT NurExone (OTC:NRXBF) is a clinical stage biotech company that is developing an off-the-shelf, non-invasive and novel treatment for the reversal or reduction of paralysis following spinal cord injury using exosome-based (membrane-bound extracellular vesicles) patent-pending technology. But that one sentence description fails to
- GlobeNewswire
NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M
TORONTO and HAIFA, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company developing exosome-based therapies for the multi-billion dollar regenerative medicinei market, is pleased to announce a non-brokered private placement of up to 3,636,363 units (“Units”) at a price of $0.55 per Unit for aggregate gross proceeds of up to $2,000,000 (the “Offering”) and will, on acceptance of the
